Media Fill A Process Simution. Presented By Shikha Chauhan

Similar documents
FDA s Guidance for Industry

Aseptic Process Validation

Annex A2. Guidance on Process Validation Scheme for Aseptically Processed Products

Review Validation of aseptic processes for pharmaceuticals

Aseptic Processing Practices and Process Validation of Aseptic Operators

Guidance for Industry

Overview of a sterility assurance program for PET drugs

Overview of Inspection Issues with Legacy Products

GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS

Validation Study on How to Avoid Microbial Contamination during Pharmaceutical Production

Preparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014

Hot Topics in Drug Product Process Validation: A Reviewer s Perspective

ANNEX 1: COMMENT SUBMISSION DOCUMENT

Overview and Introduction Annex 1 Revision

VALIDATION OF ASEPTIC PROCESSES

Complaints Investigations Root Cause Analysis

Environmental Monitoring of Aseptic Processing Areas - 1

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.

Microbiological Consideration for Non-Sterile Pharmaceutical

HISTORY AND MILESTONES

How to Handle Excursions in Environmental Monitoring (EM) and Personnel Monitoring (PM) in an Aseptic Processing Plant

CGMP for Phase 1 INDs

Environmental Monitoring of Aseptic Processing Areas - 2

Current Trends in Sterile Manufacturing. by Sterling Kline, RA Director of Project Development Integrated Project Services (IPS)

BIO & PHARMA ANALYTICAL TECHNIQUES

Guidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE

Curriculum Vitae. SENIOR VICE PRESIDENT JAMES P. KULLA Mobile Phone:

Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services

PDA: A Global. Association. Matrix Approach to Media Fills. (c) 2012 Catalent Pharma Solutions. All rights reserved.

Incremental GMPs. Presented by: Karen S. Ginsbury For: IFF October 31, Nov 02, PCI Pharmaceutical Consulting Israel Ltd.

SITE MASTER FILE For MHRA

Health Products and Food Branch Inspectorate

Media Fill Evaluations in Cellular Therapy Product Manufacturing: Three Possible Approaches. Doug Padley Mayo Clinic

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE: MANUFACTURE OF THE FINISHED DOSAGE FORM

Deficiencies found in Inspections and QP Responsibilities

Validation Needs for Sterilization by Aseptic Filtration

HVAC and Risk Management RACI Meeting 7 th December Agenda. Design. Project Management. Context. Qualification. Construction

Microbiology Testing: USP requirements for Sterile and Nonsterile Preparations Webinar Q&A

PHCT 401 Aseptic Processes & Techniques

IN THIS SECTION MICROBIOLOGY TESTING EXPERT SOLUTIONS FOR PRODUCT DEVELOPMENT. Bacterial Endotoxin (LAL) Testing

GUIDE TO INSPECTIONS OF MICROBIOLOGICAL PHARMACEUTICAL QUALITY CONTROL LABORATORIES

Managing Aseptic Interventions

Allergy Laboratories, Inc. 10/4/13

Environmental Control Requirements. Gordon Farquharson July 2017

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

Managing Your Environmental Isolates

Overview of Inspection Issues with Legacy Products. Barbara Breithaupt Consumer Safety Officer

Points to Consider for Aseptic Processing Part 2 May 2016

The Parenteral Drug Association

Modular Turnkey Concept for Pharmaceutical Sterile Formulation Facilities

Summary of USP* 797 Pharmaceutical Compounding Sterile Preparations

Supplementary Training Modules on Good Manufacturing Practice. Validation. WHO Technical Report Series, No. 937, Annex 4.

illatu/fill/seal Packaging System

Aseptic Processing Current Issues & Trends

Overview of Regulatory Requirements for API and Formulations

Compounding Pharmacies and the USP <71> Sterility Tests

Risk based approaches for a sterility assurance application review: a microbiologist s perspective Dr. Yeissa Chabrier Roselló

September 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

Bioburden Contamination Control: A Holistic Overview

á61ñ MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: MICROBIAL ENUMERATION TESTS

Why change is inevitable in aseptic manufacturing?

GMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides

PhEn-602 Notes # 4 J. Manfredi

Inspections, Compliance, Enforcement, and Criminal Investigations

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union

Guidance for Industry Sterile Drug Products Produced by Aseptic Processing Current Good Manufacturing Practice

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould

Tests to Support Sterility Claim. Imtiaz Ahmed

Managing Your Environmental Isolates

GOOD MANUFACTURING PRACTICE

Guidance for Industry Process Validation: General Principles and Practices; A Contract Manufacturing Organization's Approach

Driving Value through Innovation in Biotech Manufacturing. Agenda

MASTER PLANNING FOR VALIDATION

for IND and RDRC Regulated PET Compounding

Drug, Device and Diagnostic Manufacturing

Guidance for Industry

MICROBIOLOGICAL BEST LABORATORY PRACTICES USP <1117>

Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex

Contamination Risk Assessment in Aseptic, Non-Sterile and Terminally Sterilized Products March 7 th & 8 th Raleigh, NC

Contents. Contents (13) 1 Production (23)

Method Suitability Report Membrane Filtration Sterility Test with QTMicro Apparatus

EU and FDA GMP Regulations: Overview and Comparison

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. This document is for consultation until 11 December 2015

Emcure Pharmaceuticals Limited 3/3/16

21CFR Ventilation, air filtration, air heating and cooling. 21CFR211 Details, Details. 21CFR Equipment Cleaning and Maintenance

Growth Promotion Test Guide for Media Used in Sterility Tests

EudraLex. Part I1 Chapter 6: Quality Control

Proposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding <823>

DESIGNING YOUR ENVIRONMENTAL MONITORING PROGRAM FOR MOLD. Presented by Aaron Bisceglia

Disinfection Qualification Testing

Facility and Operational Issues for Cord Blood Banks: FDA Draft Guidance

On behalf of the PHSS Pharmaceutical and Healthcare Sciences Society (UK).

GUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET

DISINFECTION QUALIFI CATION TESTING CONSIDERATIONS FOR THE ASEPTIC AND CLEANROOM MANUFACTURING ENVIRONMENT

Regulatory Aspects of Cleaning and Cleaning Validation. Larry Greenstein Quality Operations, Quality Unit, Bio-Technology General, Ltd.

INSTRUCTIONS FOR USE

EU GMP ANNEX 1 CHANGES CLARIFICATION AND IMPACT

Good manufacturing practices

Transcription:

Media Fill A Process Simution Presented By Shikha Chauhan

21 CFR 211.113 Validation of Aseptic Processing and Sterilization Process Simulation / Media Fill Filtration Efficacy Sterilization of Equipment, containers and closures

What is Media Fill? Includes exposing the microbiological growth medium to product contact surface of equipment, container closure systems, critical environments, and process manipulations to closely simulate the same exposure that the product itself will undergo.

What should be considered for a media fill? 1. Study design 2. Frequency and number of runs 3. Duration of runs 4. Size of runs 5. Line speed 6. Environmental conditions 7. Media 8. Incubation and examination of media filled units 9. Interpretation of test results

1. STUDY DESIGN a. Factors associated with longest permitted runs b. Interventions i. Routine ii. Non routine c. Lyophilization, when applicable d. Aseptic assembly of equipment e. Number of personnel f. Aseptic additions/transfers

j. Shift changes k. Gown changes l. Aseptic sample collection m. Line speed and configuration n. Weight checks o. Container closure system p. Written procedures

2. FREQUENCY AND NUMBER OF RUNS a. Initial Qualification of line i. To be repeated enough times ii. Atleast three consecutive separate successful runs required b. Subsequent routine qualification i. Semi-annual for each line

C. Additional qualification required in case of i. Facility and equipment modification ii. Line configuration changes iii. Significant changes in personnel iv. Anomalies in environmental testing results v. Container closure system changes vi. Extended shut downs vii.end point sterility failures

d. Post failure media fill Cause detected Cause not detected Three consecutive successful runs required

3. DURATION OF RUNS a. Full Batch size and duration is the ideal run b. Manual filling/closing c. Extensive Manual manipulation d. Fully automated procedure

4. SIZE OF RUNS a. For a batch size of less than 5,000 units Atleast equal to the maximum batch size a. For a batch size of 5,000 units or more Generally acceptable starting point 5,000 to 10,000 units

Factors affecting run size Actual batch size Type of operation manual/mechanical Time consumed Type of facility open/isolated

5. LINE SPEED Range of line speeds addressed One media fill one line speed

6. ENVIRONMENTAL CONDITIONS Actual Conditions Stressful conditions inline with SOPs

7. MEDIA Routine: Soybean caesin digest medium Exceptional: Fluid thioglycollate medium Growth promotion demonstration Bacteria Gram +ve Gram-ve Yeast and mold

Size of innoculum Less than 100 CFU Failure of growth promotion and origin of contamination during simulation be investigated and media fill to be repeated

8. INCUBATION AND EXAMINATION OF MEDIA-FILLED UNITS Temperature 20-35ºC Set temperature + 2.5ºC of target temperature Time Lower temperature 7 days Higher temperature 7 days

Examination Pre-incubation Integral units to be incubated Units lacking integrity to be rejected After-Incubation is underway Selection/Rejection of damaged units to be justified Written procedure for aseptic intervention should be clear and specific

9. INTERPRETATION OF TEST RESULTS Contaminated units to be considered objectionable Microorganism to be identified to species level. Contamination indicative of potential sterility assurance problem, regardless of run size

Batch Size Number of contaminated units Less than 5000 zero OK One 5000 to 10,000 zero OK One two Interpretation Revalidation Investigate and consider repeat Revalidation More than 10,000zero OK One two Investigate and consider repeat Revalidation

Observed number of failures 0 1 2 3 4 5 6 7 8 9 10 Upper 95% confidence limit 3 4.74 6.3 7.75 9.15 10.51 11.84 13.15 14.43 15.71 16.96

Contamination rate = Upper confidence limit/number of filled units X 100% Accepted contamination rate should be less than 0.1% with a 95% confidence level

CONSIDERATIONS FOR EACH DOSAGE FORM Liquid products Injectable Powder products Suspension products Freeze Dried products

Semi-Solid products Clinical trials material and small batch size products Biological and Biotechnology products Sterile Bulk Pharmaceuticals Blow Fill Seal Packed products

SOURCES OF CONTAMINATION Aseptic practices Poor aseptic connections Poor sanitization Construction Poor gown design New line s HVAC installation Velocity thru HEPA filters Mechanical failure

References 21 CFR 211.63 21 CFR 211.65 21 CFR 211.67 21 CFR 211.84 (c) 21 CFR 211.100(a) 21 CFR 211.113(b)

Thank You